DouglasAArenbergMD

Pulmonology • Ann Arbor, MI

Critical Care Medicine, Interventional Pulmonology, Thoracic Oncology

Professor of Medicine, Pulmonary & Critical Care Medicine

Join to view full profile

Dr. Arenberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Arenberg's full profile

Already have an account?

Office
1150 West Medical Center Dr.
6301 MSRB III SPC 5642
Ann Arbor, MI 48109
Phone+1 734-647-6477

Fax+1 844-857-3177

Summary

Dr. Arenberg is a Pulmonary and Critical Care Physician in Ann Arbor, MI affiliated with Michigan Medicine VA Ann Arbor, and University of Michigan Medical Medical School. He received his medical degree from University of Illinois College of Medicine and has been in practice for over 30 years. He specializes in lung cancer diagnosis, staging, prevention and early detection.

Welcome to T-cubed (Tobacco Treatment Tips)

Provider oriented information on assessing and treating tobacco dependence

Education & Training

University of MichiganFellowship, Pulmonary Disease and Critical Care Medicine, 1996
University of Michigan Medical Center1993
University of MichiganResidency, Internal Medicine, 1993
University of MichiganInternship, Internal Medicine, 1990 - 1991
University of Illinois College of MedicineClass of 1990
University of Illinois at Urbana-ChampaignB.S., Bioengineering, 1986

Certifications & Licensure

MI State Medical License 1990 - 2026
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Clinical Excellence Society Department of Internal Medicine
America’s Best Doctors 2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
TAMS Award (Token of Appreciation from Medical Students) 2004
Physician-Investigator Award for Excellence in Research 2000
Kimmel Foundation Scholar 1998
Henry Christian Award for Excellence in Cancer Research 1993
Fellow 1993
Award for Outstanding Senior Resident Research Project 1993
Senior Honor Award Nominee 1990
Alpha Omega Alpha Medical Honor Society 1989
Otto Saphir Memorial Scholarship 1989
Book Award for First Year Class 1987
Phi Kappa Phi Honor Society 1986
Dean's List 1983
Delta Chi Fraternity 1982
Join now to see all

Clinical Trials

Validation of a Multi-gene Test for Lung Cancer Risk Start of enrollment: 2011 May 01
Active, not recruiting
Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy in the Lung Start of enrollment: 2013 Feb 01
Completed
NAVIGATE: Clinical Evaluation of superDimension™ Navigation System for Electromagnetic Navigation Bronchoscopy™ Start of enrollment: 2015 Apr 16
Completed

Publications & Presentations

PubMed

64 citations
Improved survival in tumor-bearing SCID mice treated with interferon-γ-inducible protein 10 (IP-10/CXCL10)
Douglas A. Arenberg, Eric S. White, Marie D. Burdick, Scott R. B. Strom, Robert M. Strieter
Cancer Immunology, Immunotherapy. 2001-12-01
146 citations
The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the For...
Frank C. Detterbeck, Andrew G. Nicholson, Wilbur A. Franklin, Edith M. Marom, William D. Travis
Journal of Thoracic Oncology. 2016-05-01
107 citations
The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis.
Christina L. Addison, Douglas A. Arenberg, Susan B. Morris, Ying Ying Xue, Marie D. Burdick
Human Gene Therapy. 2000-01-20

Journal Articles

Nodule Volume Measurement: pushing the Pendulum
Arenberg, DA, Chest, 3/1/2014
Implementation of a Lung Cancer-Screening Program
Arenberg DA, Current Surgery Reports, 1/1/2013
IASLC CT Screening Workshop 2011: Expert Pulmonary Group International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report
Field JK , et al, J Thorac Oncol, 1/1/2012
Changes in Global Function and Regional Ventilation and Perfusion on SPECT During the Course of Radiotherapy in Patients with Non-small Lung Cancer
Yuan ST, Frey KA, Gross MD, Hayman JA, Arenberg DA, Cai XW, Ramnath N, Hassan K, Moran J, Eisbruch A, Ten Haken RK, Kong FM, Int J Radiat Onco Biol Phys, 1/1/2012
Semiquantification and Classification of Local Pulmonary Function by V/Q Single Photon Emission Computed Tomography in Patients with Non-small Cell Lung Cance: Potenti...
Yuan ST, Frey KA, Gross MD, Hayman JA, Arenberg DA, Curtis JL, Cai XW, Ramnath N, Kalemkerian GP, Ten Haken RK, Eisbruch A, Kong FM, J Thorac Onco, 1/1/2011
Invited Editorial PET scans for spolitary pulmonary nodules: Costs and cost effectivelness
Arenberg, DA, Chest, 1/1/2010
Time to Treatment in Patients with Stage III Non-small Cell Lung Cancer
Wang L, Correa CR, Hayman JA, Zhao L, Cease K, Brenner D, Arenberg D, Curtis J, Kalemkerian GP, Kong FM, Int J Radiat Oncol Biol Phys, 7/1/2009
Expression of CD74, the Receptor for Macrophage Migration Inhibitory Factor (MIF), in Non-Small Cell Lung Cancer
McClelland MR, Zhao L, Carskadon SL, Arenberg DA, Am J Pathol, 1/1/2009
Chemokines in the biology of lung cancer
Arenberg DA, J Thoracic Onc, 1/1/2006
Peroxisome proliferator activated receptor-gamma activation inhibits tumor progression in non-small cell lung cancer
Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, Standiford TJ, Oncogene, 1/1/2004
Chemokines as therapeutic targets in non-small cell lung cancer
Arenberg D, Med Chem Rev Online, 1/1/2004
Lung cancer: selecting patients for surgery
Arenberg D, J Resp Dis, 1/1/2004
Evaluating the patient with suspected lung cancer
Arenberg D, J Resp Dis, 1/1/2004
Invited Editorial In search of the Holy Grail: Lung Cancer Biomarkers
Arenberg, DA, Chest, 1/1/2004
Macrophage migration inhibitory factor (MIF) and CXC chemokine expression in human non-small cell lung cancer (NSCLC): role in angiogenesis and prognosis
White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, Orringer MB, Arenberg, DA, Clin Can Res, 1/1/2003
White ES, Carskadon SL, Dickey EG, Livant DL, Markwart S, Arenberg DA, Am J Resp Crit Care Med, 1/1/2003
Chemokines as therapeutic targets in non-small cell lung cancer
White EW, Strieter RM, Arenberg DA, Curr Med Chem Anticancer Agents, 1/1/2002
RANTES expression by lung adenocarcinoma is a predictor of survival in stage I patients
Moran CJ, Arenberg DA, Huang C, Giordano TJ, Thomas DG, Misek DE, Hanash S, Iannettoni MD, Orringer MB, Beer DG, Clin Can Res, 1/1/2002
Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity
White EW, Strom SR, Wys NB, Arenberg DA, J Immunol, 1/1/2001
Monocyte-fibronectin interactions, via alpha5beta1 integrin, induce expression of CXC chemokine dependent angiogenic activity
White EW, Livant DL, Markwart S, Arenberg DA, J Immunol, 1/1/2001
Overexpression of CXC-chemokines by an adrenocortical carcinoma: A novel clinical syndrome
Schteingart DE, Giordano TJ, Benitez R, Burdick M, Starkman MN, Arenberg DA, Strieter RM, J Clin Endocrinol Metab, 1/1/2001
The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer model
Arenberg DA, Zlotnick A, Strom SR, Burdick MD, Strieter RM, Cancer Immunol Immunother, 1/1/2001
Improved survival in tumor bearing SCID mice treated with interferon-gamma-inducible protein 10 (IP-10/CXCL10)
Arenberg DA, White ES, Burdick MD, Strom SR, Strieter RM, Cancer Immunol Immunother, 1/1/2001
CXC chemokines in angiogenesis
Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM, J Leuk Biol, 1/1/2000
The CXC chemokine, monokine induced by interferon gamma (MIG), inhibits non-small cell lung cancer (NSCLC) tumor growth and metastasis
Addison C, Arenberg DA, Morris SB, Xue Y, Burdick MD, Mulligan MS, Iannetoni MD, Strieter RM, Hum Gene Ther, 1/1/2000
Join now to see all

Books/Book Chapters

Clinical Respiratory Medicine
Chapter: Lung cancer Treatment, Chapter 67
Arenberg, DAEditors: S. Spiro, G.A. Silvestri, and A. Agusti.Edition 4th,2012
Novel Biological Mechanisms and Impact on Clinical Practice.
Chapter: Angiogenic diversity and lung cancer metastasis in Lung Cancer Metastasis
Arenberg, DAEditors: V. Keshamouni, D. Arenberg, and G. Kalemkerian.Springer, New York, NY2009
Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on Clinical Practice.
Editors: V. Keshamouni, D. Arenberg, G. Kalemkerian.Springer, New York, NY2009
The Cytokine Handbook
Chapter: Macrophage migration inhibitory factor (MIF). Chapter 45
Page 1037 - 1048Arenberg DA and Bucala REditors: A. Thomson and M. Lotze.Academic Press, London, UKEdition 4th,2003
Inflammation: Basic Principles and Clinical Correlates.
Chapter: Angiogenesis.
Page 851 - 864Arenberg DA, Strieter RMEditors: J. Gallin and R. Snyderman.Lippincott Williams & Wilkins, Philadelphia, PAEdition 3rd,1999
Chemokines and Cancer
Chapter: CXC chemokines and lung cancer angiogenesis.
Page 3 - 19Strieter RM, DiGiovine B, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R, Arenberg DAEditors: Barrett J. Rollins.Humana Press, Totowa, NJ1999
Chemokines in Disease: Biology and Clinical Research.
Chapter: The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer.
Page 171 - 182Strieter RM, Addison CA, Moore BB, Arenberg DAEditors: C. Hebert.Humana Press, Totowa, NJ1999
Molecular and Cellular Basis of Inflammation.
Chapter: Angiogenesis.
Page 29 - 49Arenberg DA, Strieter RMEditors: C. Serhan and P. Ward.Humana Press, Totowa, NJ1999
The Role of Chemokines in Disease.
Chapter: The role of CXC chemokines in regulation of angiogenesis.
Page 195 - 210Strieter RM, Kunkel SL, Shanafelt AB, Arenberg DA, Koch AE, Polverini PJEditors: A. Koch and R. Strieter.Landes Co. Publishers, Austin, TX1996
Murray & Nadel’s Textbook of Respiratory Medicine
Chapter: Metastatic Lung Tumors. Chapter 49
Arenberg, DA, Pickens, AEditors: Mason, R., Broaddus, V.C., King, T., Schraufnagel, D., Martin, T.R., Murray, J.F., Nadel, J..Edition 5th,
Join now to see all

Abstracts/Posters

Lung injury accelerates growth of lung cancer cells in an orthotopic model of lung cancer.
Arenberg DA, Carskadon SL, Zhao L, American Thoracic Society, Toronto, Ontario, Canada, 5/1/2008
The tumor microenvironment modulates the angiogenic phenotype in lung cancer. Diversity and plasticity of the angiogenic switch in lung cancer.
Arenberg DA, Carskadon SL, Zhao L, White ES McClelland MR, American Thoracic Society, San Diego, CA, 5/1/2007
Diversity and plasticity of the angiogenic switch in lung cancer.
McClelland MR, Carskadon SL, Zhao L, White ES, Arenberg DA, American Thoracic Society, San Diego, CA, 5/1/2006
Tumor derived fibroblasts are pro-angiogenic.
McClelland M, Gray A, Carskadon S, Zhao L, and Arenberg DA, American Thoracic Society, San Diego, CA, 5/1/2005
Oxidase-Dependent Expression of Angiogenic Activity by Non-small Cell Lung Cancer Cells
Arenberg DA, Carskadon SL, Thannickal VJ and Keshamouni, V, American Thoracic Society, Orlando, FL, 5/1/2004
Tumor Derived Fibroblasts in Lung Cancer; A Distinct Sub-population of Lung Fibroblasts.
Arenberg DA, Gray A, Carskadon SL, White ES, AACR, Orlando, FL, 3/1/2004
GP91phox-dependent Expression of Angiogenic CXC Chemokines in Human Non-Small Cell Lung Cancer.
Arenberg DA, Carskadon SL, Thannickal VJ, The Thomas Petty Aspen Lung Conference, 6/1/2003
H2O2-dependent Expression of Angiogenic CXC Chemokines by Human Non-Small Cell Lung Cancer Cells.
Arenberg DA, Carskadon SL, Thannickal VJ, AACR, Toronto, Ontario, Canada, 4/1/2003
Evidence for Selective PPAR Modulation in Lung Cancer.
Keshamouni V, Joel B, Reddy R, Arenberg DA, Standiford T, Keystone Symposia on PPAR, 2/1/2003
Basement Membrane Invasion by Lung Fibroblasts from IPF: Role of paxillin and pp125FAK.
White ES, Carskadon SL, Dickey EG, Arenberg DA, ATS, Seattle, WA, 1/1/2003
Peroxisome Proliferator-Activated Receptor (PPAR) Agonists Impede Growth in Non-Small Cell Lung Cancer By Inhibiting Cell Proliferation and Angiogenesis.
Keshamouni V, Reddy R, Joel B, Arenberg DA, Newstead M, Standiford T, ATS, Seattle, WA, 1/1/2003
Redox regulation of apoptotic resistance in lung cancer cells.
Keshamouni V, Arenberg DA, Joel B, Reddy R, Standiford T, Thannickal VJ, ATS, Seattle, WA, 1/1/2003
Macrophage Migration Inhibitory Factor (MIF) Promotes Chemokine Mediated Angiogenesis In Lung Cancer.
Arenberg DA, White ES, Carskaddon S, ATS, Seattle, WA, 1/1/2003
Invasive Behavior of Lung Fibroblasts from Fibrotic Diseases: Role of the alpha4beta1 and alpha5beta1 Integrins.
White ES, Carskadon SL, Dickey EG, Arenberg DA, ATS, Seattle, WA, 1/1/2003
Expression of macrophage migration inhibitory factor (MIF) in human non-small cell lung cancer (NSCLC).
Arenberg DA, Carskaddon S, White ES, Midwest Section-AFMR, Chicago, IL, 9/1/2002
Fibrotic-lung fibroblast invasion of basement membranes is modulated by PTEN.
White ES, Carskadon SL, Livant DL, Markwart S, Toews GB, Arenberg DA, Am J Respir Crit Care Med, 1/1/2002
Macrophage infiltration of murine lung cancer tumors: role in angiogenesis.
Arenberg DA, White E and Carskaddon S, Am J Respir Crit Care Med, 1/1/2002
Macrophage migration inhibitory factor (MIF) in pulmonary fibrosis.
Lama VN, Arenberg D, Flaherty K, Moore B, Kazerooni E, Standiford T, Toews G, Martinez FJ, Am J Respir Crit Care Med, 1/1/2002
Induction of chemokine dependent angiogenic activity by macrophage migration inhibitory factor (MIF).
Arenberg DA, Wys NL, and White E, Keystone Symposium on Chemokines and Chemokine Receptors, Taos, NM, 2/1/2001
Inhibition of lung cancer derived chemokine expression by atorvastatin.
Arenberg DA and Wys N, FASEB J, 1/1/2001
Migration inhibitory factor (MIF) expression in lung cancer promotes angiogenesis.
Arenberg DA, Wys N, White ES, Am J Respir Crit Care Med, 1/1/2001
White ES, Wys NL, and Arenberg DA, Am J Respir Crit Care Med, 1/1/2001
Fibronectin is a Key Mediator of Macrophage-Derived Angiogenic Activity.
White ES, Wys N, Strom SR, Arenberg D, Cytokines and Cancer: Regulation, Angiogenesis, and Clinical Applications. American Association for Cancer Research, 9/20/2000
In vitro interaction between non-small cell lung cancer cells and monocytes.
White ES, Strom SR, Arenberg DA, Am J Respir Crit Care Med, 1/1/2000
IL-12 attenuates bleomycin-induced pulmonary fibrosis by inducing expression of IFN-gamma.
Keane MP, Belperio JA, Arenberg DA, Burdick MD, Strieter RM, Am J Respir Crit Care Med, 1/1/2000
Join now to see all

Lectures

Cellvizio Pulmonary Roundtable Discussion. Invited Speaker
12/1/2014
Emerging Science and Therapies in Lung Cancers
New York, NY - 11/1/2014
Key Components of a Lung Cancer Screening Program. Invited Speaker
Gratiot Hospital, Midland, MI - 11/1/2014
Lung Cancer Evaluation and Treatment: an Evolving Paradigm. Chair, Invited Speaker
Austin, TX - 10/1/2014
Bais, Bonsuses and Benfits: Understanding of Data from Lung Cancer Screening Trails. Invited Speaker
Troy, MI - 10/1/2014
PET Scans: The Swiss Army Knife of Thoracic Oncology. Chair and Invited Speaker
Austin, TX - 10/1/2014
What is Multifocal Lung Cancer, and How Do We Manage IT? Panel Discussion
Austin, TX - 10/1/2014
Pulmonary Nodule Workup
University of Michigan , Ann Arbor, MI - 9/10/2014
Technical and Practical Aspects fo Bronchscopy
University of Michigan , Ann Arbor, MI - 9/6/2014
Lung Cancer Screening
University of Michigan , Ann Arbor, MI - 8/8/2014
Cell and Molecular Biology Lecture
Chicago, IL - 8/1/2014
Neoplasms Lecture
Chicago, IL - 8/1/2014
Implementation of Lung Cancer Screening. Invited Speaker and Participant
San Deigo, CA - 5/1/2014
Diagnosis and Management of Lung Cancer. Chair and Speaker
San Antonio, TX - 3/1/2014
Diagnostic Approach to the Patient With Suspected Lung Cancer. Invited Speaker
Chicago, IL - 10/1/2013
ACCP Lung Cancer III Guidelines: Treatment of Early Lung Cancer (NSCLC). Speaker
Chicago, IL - 10/1/2013
Present and Future Targeted Lung Cancer Therapy: Beginning the End of Nihilism. Chair and Invited Speaker
Chicago, IL - 10/1/2013
Lung Cancer Screening: Practical Lessons From Early Experiences. Invited Speaker
Chicago, IL - 10/1/2013
Synergistic Perspectives in NSCLC Management. Invited Speaker
Chicago, IL - 9/1/2013
Pulmonary Board Review. Invited Speaker
Chicago, IL - 8/1/2013
Lung Cancer
University of Michigan , Ann Arbor, MI - 7/19/2013
Diagnosis and Staging of Lung Cancer
University of Michigan , Ann Arbor, MI - 7/9/2013
Internal Medicine Update, Speaker
Mackinac Island, MI - 7/1/2013
Lung cancer Screening: Moving Forward. Symposium Chair and Speaker
5/1/2013
Lung cancer screening: Evidence Based Review
5/1/2013
Join now to see all

Press Mentions

The Shifting Sands of Lung Cancer ScreeningJuly 18th, 2022
The Shifting Sands of Lung Cancer ScreeningJuly 18th, 2022
Experts Say More People Should Get Lung Cancer Screenings, and SoonerJuly 20th, 2020
Join now to see all

Grant Support

Promotion Of Angiogenesis In Lung Cancer By MIFNational Cancer Institute2002–2010
IP-10 As An Angiostatic Factor In Lung CancerNational Cancer Institute1997–2001

Committees

Board Member, American College of Chest Physicians Board of Regents 2019 - Present
Panel Member, NCCN Tobacco Cessation Guidelines Panel 2016 - Present
Member, IASLC Smoking Cessation and Tobacco Policy Committee 2014 - Present